Mineralys Therapeutics, Inc.
MLYSNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $1.74B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $20.12$47.65
- Volume (live)
- -
- Avg. volume (3M)
- 1.38M
Mineralys Therapeutics (MLYS) Stock Price & Financial Analysis
Mineralys Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $20.32 - $21.38 |
|---|---|
| 52-Week High | $47.65 |
| 52-Week Low | $20.12 |
| Open | $21.38 |
| Volume (last close) | 1.09M |
| Average Volume (3M) | 1.38M |
| 50-Day MA | $25.69 |
|---|---|
| 200-Day MA | $27.53 |
| 1-Year Change | −47.39% |
| Market Cap | 1.74B |
|---|---|
| Shares Outstanding | 84.73M |
| Price to Book (P/B) | 3.16 |
| EV/EBITDA | -5.03 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Mineralys Therapeutics at a Glance
As of the Oct 23, 2026 close, Mineralys Therapeutics (MLYS) has a market capitalization of $1.74B.
As of its latest reported balance sheet, it holds $138.27M in cash and securities against $97.62M of debt, a net cash position of $40.65M.
Mineralys Therapeutics does not currently pay a dividend.
The share price is down 47.4% over the past year. At $20.55 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $20.12 to $47.65, below its 200-day moving average of $27.53.
Based on 7 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $51.00, 148.2% above the Oct 23, 2026 close.
Frequently Asked Questions About Mineralys Therapeutics
What is the current stock price for MLYS?
As of the Oct 23, 2026 close, MLYS stock trades at $20.55. The 52-week range is $20.12–$47.65, with a day range of $20.32–$21.38.
What is the P/E ratio for MLYS?
The P/E ratio (Price-to-Earnings) for MLYS is shown in the Key Statistics section. This valuation metric helps compare Mineralys Therapeutics, Inc. to industry peers.
Does MLYS pay dividends?
Mineralys Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for MLYS?
Based on ratings from 7 professional analysts over the last 90 days, the consensus for MLYS is Buy. The average 12-month price target is $51.00, a 148.2% upside from the Oct 23, 2026 close of $20.55.
What is the market cap of MLYS?
As of the Oct 23, 2026 close, Mineralys Therapeutics's market capitalization is $1.74B, classifying it as a small-cap company. Mineralys Therapeutics operates in the Healthcare sector within the Biotechnology industry.